ATLANTA, May 03, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the first quarter ended March 31, 2017, after the close of the financial markets on May 8, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. Management will also be joined by Dr. Christopher Riemann, volunteer professor at the University of Cincinnati department of ophthalmology and member of the board of directors of the Cincinnati Eye Institute to discuss his direct experience with patient outcomes and demand for ILUVIEN. The call will be held at 8:00 AM ET, on Tuesday, May 9, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference date: Tuesday, May 9th, 2017, 8:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' First Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 firstname.lastname@example.org
Source:Alimera Sciences, Inc.